Vim li cas Standard Antivirals tsis ua hauj lwm? Engineering Baloxavir Marboxil API (CAS 1985605-59-1)
Aug 20, 2026
Tso lus
Vim li cas Standard Antivirals tsis ua hauj lwm? Engineering Baloxavir Marboxil API (CAS 1985605-59-1)
Ib daim ntawv R&D Whitepaper ntawm Cap-Dependent Endonuclease Inhibition, Chiral Prodrug Synthesis, thiab End of Oseltamivir Resistance.
Tsis tas li ntawd, cov tshuaj tiv thaiv kab mob qub txeeg qub teg yuav tsum muaj qhov hnyav, nruj 5- hnub noj tshuaj. Hauv kev saib xyuas menyuam yaus thiab cov laus, cov tshuaj tsis ua raws li -, ua rau kev kho tsis ua haujlwm. Kev lag luam tau thov kom muaj kev hloov pauv hloov pauv-ib lub cev muaj peev xwm tshem tawm tus kab mob hauv ib zaug, cais tshuaj.Baloxavir Marboxil (CAS 1985605-59-1)yog cov lus teb. Raws li thawj-hauv-chav kawm cap-dependent endonuclease inhibitor, nws tawm tsam tus kab mob ntawm qhov sib txawv, ua ntej theem ntawm nws lub voj voog rov ua dua. Cov ntaub ntawv thev naus laus zis no nthuav tawm qhov tshwj xeeb "cap-snatching" inhibition mechanics ntawm Baloxavir, nthuav tawm cov kev txwv ntawm cov kev cuam tshuam qub txeeg qub teg, thiab qhia txog qhov tseeb, siab -purity chiral chemical synthesis raws tu qauv ua tiav ntawm Xi'an Tihealth.
1. Molecular Architecture: Ntiav Viral "Cap-Snatching" Mechanism
Txhawm rau kom ua tiav cov txiaj ntsig Baloxavir Marboxil hauv cov kav xa dej siab tshaj plaws, cov thawj coj tshawb fawb yuav tsum nkag siab txog lub hom phiaj kab mob uas ua rau cov molecule no ua rau muaj kev puas tsuaj rau Influenza A thiab B. Baloxavir Marboxil (C.27H23F2N3O7S) yog ib qho khoom lag luam sophisticated. Thaum noj, nws hloov mus rau nws daim ntawv nquag, Baloxavir, uas yog lub hom phiaj ntawm kev txuag, tsis yog -mutating core enzyme ntawm tus kab mob.
Inhibiting Polymerase Acid (PA) Protein
Cov kab mob khaub thuas tsis muaj lub tshuab los tsim lawv tus kheej mRNA lub kaus mom, uas yuav tsum tau txhais los ntawm tus tswv ribosomes. Txhawm rau kom muaj sia nyob, tus kab mob no siv cov txheej txheem hu ua "cap-snatching," qhov twg nws cov protein ntau Polymerase Acidic (PA) ua cov endonuclease txhawm rau txhawm rau 5 'caps los ntawm tus tswv tsev cell's tus kheej mRNA. Baloxavir yog engineered los khi qhia meej rau qhov chaw nquag ntawm lub hau no -dependent endonuclease. Los ntawm chelate ob qhov tseem ceeb catalytic manganese (Mn2+los yog magnesium (Mg2+) ions nyob rau hauv lub active hnab tshos, Baloxavir mus tas li disables lub enzyme. Yog tsis muaj lub kaus mom, tus kab mob mRNA tsis tuaj yeem muab txhais ua cov kab mob kis kab mob, thiab kev rov ua dua tshiab tas li.
Thaum ntxov-Kev cuam tshuam rau theem vs. lig-Theem tso tawm
Ib txwm neuraminidase inhibitors (xws li Oseltamivir) ua haujlwm ntawm qhov kawg ntawm kab mob viral. Lawv tiv thaiv cov virions tshiab los ntawm kev cais tawm ntawm tus tswv tsev cell. Qhov no txhais tau hais tias lub xovtooj ntawm tes tau kis tus kabmob, nyiag khoom, thiab tsim cov khoom kis kabmob. Baloxavir cuam tshuam rau theem ntxov tshaj plaws -kev hloov pauv. Vim tias nws txwv tus kab mob los ntawm kev rov ua dua nws cov genome hauv lub xov tooj ntawm tes, nws ua rau muaj kev cuam tshuam sai dua hauv cov kab mob kis hauv thawj 24 teev ntawm kev tswj hwm, txiav tawm kev sib kis sai sai.
Prodrug Mechanism rau Optimal Absorption
Lub active molecule, Baloxavir, yog absorbed tsis zoo nyob rau hauv lub plab zom mov vim nws polarity. Baloxavir Marboxil hla qhov no los ntawm esterification. Raws li ib tug prodrug, nws effortlessly dhau lipophilic plab hnyuv daim nyias nyias. Ib zaug hauv cov ntshav thiab daim siab, tus tswv tsev esterases sai sai hydrolyze cov pab pawg marboxil ester, tso cov tshuaj nquag mus rau hauv lub cev. Qhov kev tsim tshuaj kho mob zoo nkauj no yog qhov tso cai rau cov tshuaj siv rau qhov ncauj nrog cov bioavailability siab.
2. Forensic Formulation Matrix: Baloxavir Marboxil vs. Oseltamivir
Rau cov pab pawg muag tshuaj, kev kho mob zoo tshaj ntawm Baloxavir Marboxil sawv cev rau kev hloov pauv loj hauv kev npaj kis thoob ntiaj teb thiab cov tswv yim kho mob khaub thuas raws caij nyoog.
| Clinical & Pharmacological Parameter | Legacy NAI (piv txwv li Oseltamivir) | Xi'an Tihealth Baloxavir Marboxil API (CAS 1985605-59-1) |
|---|---|---|
| Mechanism ntawm Action | Late Stage: Inhibits viral tso tawm ntawm tes | Thaum Ntxov: Inhibits viral mRNA transcription |
| Yuav Tsum Tau Siv Tshuaj | Ob zaug ib hnub rau 5 hnub tas mus li (10 koob) | Ib leeg, cais qhov ncauj koob tshuaj (100% ua raws) |
| Viral Shedding txo | Nruab nrab (~ 72 teev kom tshem tau cov kab mob titers) | Ceev ceev (< 24 hours to halt contagiousness) |
| Resistance Profile | Ua tau zoo heev rau H275Y neuraminidase kev hloov pauv | Ua haujlwm siab tiv thaiv Oseltamivir- tiv taus avian thiab tsiaj txhu |
3. Lub Xi'an Tihealth Advantage: Mastery ntawm Polycyclic Chiral Synthesis
Baloxavir Marboxil yog qhov tsim nyog txaus ntshai. Nws muaj ib tug complex polycyclic core featuring ntau chiral centre thiab meej difluoromethyl pawg. Synthesizing no API siv rudimentary chemical pathways ua rau muaj kev puas tsuaj ntawm haiv neeg sib tov, tshuaj kuab tshuaj lom, thiab tsim cov crystalline polymorphs uas ua rau lub qhov ncauj bioavailability.
NtawmXi'an Tihealth Biotechnology Co., Ltd., peb ua tiav qhov kev tsis sib haum xeeb, ntau -cov txheej txheem organic synthesis raws tu qauv tsim kom muaj qhov tsis zoo ntawm cov tshuaj stereochemical purity thiab cov khoom ruaj khov- xeev:
Asymmetric Catalysis
Txoj kev kho mob zoo ntawm Baloxavir tso siab rau qhov tseeb 3D spatial kev npaj ntawm nws cov nplhaib polycyclic. Peb siv cov kev txiav-ntug asymmetric organocatalytic txoj kev los xyuas kom meej qhov kawg active tshuaj muaj nyob rau hauv lub enantiomeric tshaj (ee) tshaj 99.5%, tshem tawm biologically inactive thiab muaj feem xyuam rau stereoisomers.
USP<467>Solvent Control
Complex prodrug esterification yuav tsum tau organic solvents, tab sis cov khoom kho mob zaum kawg yuav tsum tsis txhob. Xi'an Tihealth ntiav cov tswv kaw -loop solvent recovery systems. Tom qab-crystallization, API yog raug mob siab heev - nqus purging, kom ntseeg tau tias cov kuab tshuaj residual poob qis qis dua qib 2 thiab Chav Kawm 3 qhov kev tswj hwm los ntawm cov kws muag tshuaj thoob ntiaj teb.
Polymorphic Verification
Baloxavir Marboxil tuaj yeem crystallize hauv ntau hom. Peb siv cov thermodynamic tswj qhov tseeb thaum lub sijhawm nag lossis daus zaum kawg, tshawb xyuas los ntawm X-ray Powder Diffraction (XRPD), los lav qhov khoom xa tuaj ntawm qhov tseeb, thermodynamically ruaj khov crystalline polymorph xav tau rau qhov siab tshaj plaws kev sib cais thiab qhov ncauj bioavailability.
4. Muaj Daim Ntawv Thov Scenario rau Baloxavir API
Vim hais tias Baloxavir Marboxil yog tsim los ua ib qho ultra-kev ua haujlwm tau zoo ib zaug- koob tshuaj, nws qhib cov khoom lag luam ua tiav tau zoo heev uas ua rau cov neeg mob ua raws li cov neeg mob thaum lub caij mob khaub thuas:
Ib leeg -Khab qhov ncauj ntsiav tshuaj
Lub hom phiaj tseem ceeb ntawm daim ntawv thov rau cov neeg laus thiab cov tub ntxhais hluas. Peb cov hmoov crystalline zoo heev tuaj yeem ua kom qhuav - sib tov lossis ntub dej -granulated nrog cov txheej txheem tshuaj excipients, compressed rau hauv cov yeeb yaj kiab ib txwm muaj- cov ntsiav tshuaj coated rau tam sim ntawd, ib qho - lub sij hawm xa tawm raws caij nyoog.
Pediatric Granules rau qhov ncauj ncua kev kawm
Ib hom ntawv tseem ceeb rau cov menyuam yaus uas nqos tsis tau cov ntsiav tshuaj. Peb API qhov ruaj khov polymorphic qauv tso cai rau nws muab sib xyaw ua ke rau hauv cov granules uas tsim kom muaj kev ruaj khov, cov kua dej tsis sib haum thaum rov tsim kho dua tshiab, ua kom muaj tseeb, ib zaug - koob tshuaj rau menyuam yaus.
Formulator & Procurement FAQ
Cov tshuaj lom neeg lom neeg molecule, Baloxavir, muaj cov pab pawg ua haujlwm zoo heev uas tsim los rau chelate hlau ions hauv tus kab mob. Hmoov tsis zoo, cov tib pab pawg no tiv thaiv cov molecule los ntawm kev hla cov lipid daim nyias nyias ntawm tib neeg txoj hnyuv. Los ntawm kev sib xyaw ua ke raws li Marboxil ester prodrug, peb ua daim npog ntsej muag ib ntus cov pawg polar, tsim kom muaj lipophilic molecule uas ua tiav qhov ncauj zoo heev. Ib zaug hauv lub cev, cov ntshav esterases tshem cov ester, ua kom cov tshuaj.
Prodrug esters tuaj yeem nkag siab rau cov dej noo -induced hydrolysis. Ua raws li cov crystallization siab heev thiab precision nqus kom qhuav, API tau ntim rau hauv 25KG fiber ntau nruas lined nrog ob npaug - txheej, tshuaj- qib polyethylene (PE) hnab. Tom qab ntawd cov khoom raug kaw nyob rau hauv ib qho inert nitrogen los yog argon flush los tiv thaiv oxidative thiab hydrolytic degradation, lav lub neej ruaj khov rau thoob ntiaj teb maritime thiab huab cua.
kiag li. Xi'an Tihealth ua haujlwm nruj me ntsis hauv ISO9001: 2015 thiab GMP- cov txheej txheem ua raws. Txhua pawg lag luam ntawm Baloxavir Marboxil raug xa mus nrog cov ntaub ntawv qhia paub. Qhov no suav nrog Daim Ntawv Pov Thawj Kev Ntsuam Xyuas (COA), siab -kev daws teeb meem HPLC chromatograms lees paub Ntau dua lossis sib npaug rau 99.0% purity, chiral purity verification (ee> 99%), thiab GC hnyav residue cov ntaub ntawv, kom ntseeg tau seamless kev koom ua ke rau hauv koj downstream R&D thiab QA cov txheej txheem
Txhim kho koj cov kav dej tiv thaiv kab mob nrog siab -purity, ib zaug - koob tshuaj prodrug APIs.
Thov HPLC Chromatogram & Bulk PricingSau los ntawm Wang Xueyan, Technical Operations & Formulation Strategy ntawm Xi'an Tihealth Biotechnology Co., Ltd.
* Kev lees paub tsis raug cai: Muab tshwj xeeb raws li qhov tsis muaj npe, kev tshawb fawb -qib Cov Khoom Siv Tshuaj (API). Cov koom haum kev yuav khoom tsuas yog lub luag haujlwm rau kev tsim kho zaum kawg, kev sim tshuaj ntsuam xyuas, thiab kev tswj hwm nruj raws li lawv txoj cai thoob ntiaj teb.*
Xa kev nug